GlaxoSmithKline plc EBIT

GlaxoSmithKline plc (GSK.SW) currently reports a EBIT of $19B as of September 2026. That compares with $5.3B in the prior-year period — up 261.1% year over year. That is below the Healthcare sector average of $130B. Use the charts on this page to explore GlaxoSmithKline plc's EBIT history and peer comparisons.

GlaxoSmithKline plc's EBIT increased from $5.3B to $19B — a 261.1% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

GlaxoSmithKline plc's EBIT of $19B is lower than the Healthcare sector average of $130B. That is roughly 85.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

GlaxoSmithKline plc reported $19B in EBIT as of September 2026. That compares with $5.3B in the prior-year period — up 261.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $19B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $130B. From there, open related valuation or income-statement pages for GlaxoSmithKline plc, and consider following GSK.SW for alerts when major investors trade the stock.